Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

摘要: BackgroundPembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), with increased tumors express ligand (PD-L1). MethodsIn this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated NSCLC PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation the epidermal growth factor receptor gene or translocation anaplastic lymphoma kinase to receive either pembrolizumab (at fixed dose 200 mg every weeks) investigator’s choice platinum-based chemotherapy. Crossover from chemotherapy group was permitted event disease progression. The primary end point, progression-free survival, assessed by means blinded, independent, central radiologic review. Secondary points were overall objective response rate, safety. ResultsMedi...